509 related articles for article (PubMed ID: 27553466)
1. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
Eiber M; Fendler WP; Rowe SP; Calais J; Hofman MS; Maurer T; Schwarzenboeck SM; Kratowchil C; Herrmann K; Giesel FL
J Nucl Med; 2017 Sep; 58(Suppl 2):67S-76S. PubMed ID: 28864615
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
6. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
7. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
13. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
[TBL] [Abstract][Full Text] [Related]
15. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
17. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ; Schottelius M
Semin Nucl Med; 2019 Jul; 49(4):302-312. PubMed ID: 31227053
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
19. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
20. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
